California State Teachers Retirement System Makes New Investment in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

California State Teachers Retirement System purchased a new position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the third quarter, Holdings Channel.com reports. The firm purchased 20,321 shares of the company’s stock, valued at approximately $180,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Schonfeld Strategic Advisors LLC purchased a new stake in Poseida Therapeutics during the 3rd quarter worth about $434,000. Boxer Capital LLC acquired a new stake in shares of Poseida Therapeutics during the third quarter worth about $11,097,000. Squarepoint Ops LLC acquired a new stake in shares of Poseida Therapeutics during the third quarter worth about $100,000. Perceptive Advisors LLC acquired a new stake in shares of Poseida Therapeutics during the third quarter worth about $6,987,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Poseida Therapeutics during the third quarter worth about $221,000.

PSTX has been the topic of a number of research analyst reports. Zacks Investment Research cut Poseida Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. William Blair reiterated a “buy” rating on shares of Poseida Therapeutics in a research report on Monday, December 7th.

Shares of PSTX stock opened at $10.97 on Friday. The firm has a market cap of $678.17 million and a PE ratio of -1.60. Poseida Therapeutics, Inc. has a 52-week low of $7.63 and a 52-week high of $17.62. The firm has a 50-day moving average of $10.62.

Poseida Therapeutics (NASDAQ:PSTX) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.08). As a group, equities research analysts forecast that Poseida Therapeutics, Inc. will post -2.93 EPS for the current year.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases.

Read More: How is an ETF different from a mutual fund?

Want to see what other hedge funds are holding PSTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Poseida Therapeutics, Inc. (NASDAQ:PSTX).

Institutional Ownership by Quarter for Poseida Therapeutics (NASDAQ:PSTX)

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.